ModeX Therapeutics, An OPKO Health Company, Announces Results From A Phase 1 Clinical Study Of SAR441236, Its Trispecific Broadly Neutralizing Antibody Against HIV, At The 2024 Conference On Retroviruses And Opportunistic Infections
Benzinga Newsdesk - Mar 5, 2024, 8:56AM